# BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Canonical URL: https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting
Ticker: BTAI
Company: BioXcel
Source: BioXcel
Published: 2026-04-17 11:00 EST
Original Source URL: https://ir.bioxceltherapeutics.com
## Summary

Live event to be held on Thursday, April 23, at 2:00 p.m. ET  Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial

## Article Body
Live event to be held on Thursday, April 23, at 2:00 p.m. ET  Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial
## Recent Company News
- 2026-05-28 11:00 EST — [BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-presents-new-data-from-serenity-at-home-phase-3-trial-for-agitation-associated-with-bipolar-disorders-or-schizophrenia-at-2026-ascp-annual-meeting) — Source: BioXcel
- 2026-05-15 11:00 EST — [BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results) — Source: BioXcel
- 2026-04-17 11:00 EST — [BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting) — Source: BioXcel
- 2026-04-08 11:00 EST — [BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-u-s-department-of-war-funded-study-of-bxcl501-sublingual-dexmedetomidine-for-treatment-of-acute-stress-reactions) — Source: BioXcel
- 2026-04-01 11:00 EST — [BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting](https://biopharmsignal.com/news/BTAI/bioxcel-therapeutics-announces-food-and-drug-administration-acceptance-of-supplemental-new-drug-application-for-use-of-igalmir-in-the-at-home-setting) — Source: BioXcel
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)